RAC 0.00% $1.94 race oncology ltd

Ann: Race investor briefing & updated presentation, page-41

  1. 31 Posts.
    lightbulb Created with Sketch. 3
    Feels like this dose escalation trial brings forward possible confirmation that Bisantrene inhibits FTO in humans by around 6 months or so?

    Which means by the end of the year, almost all the cards will be able to be laid out on the table in front of big pharma.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.